Skip to main content
Clinical Trials/ACTRN12622000218796
ACTRN12622000218796
Not Yet Recruiting
N/A

A Main Study to Determine the Diagnostic Utility of the ultrasmall superparamagnetic iron oxide (USPIO) MRI Scan in Tracking Macrophages in Patients with Glioblastoma and brain tumour metastases

Tania Slatter0 sites80 target enrollmentFebruary 7, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Stage 3 and 4 astrocytoma
Sponsor
Tania Slatter
Enrollment
80
Status
Not Yet Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 7, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tania Slatter

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients with an imaging diagnosis based on the baseline diagnostic MRI scan (gadolinium contrast) of primary stage 3 or 4 astrocytoma, or brain tumour metastasis.
  • 2\.No steroid treatment that has been administered to the patients between the time of the baseline diagnostic scan and the ferumoxytol infusion.

Exclusion Criteria

  • 1\.Patients who are younger than 18 years old.
  • 2\.Patients who are pregnant or breast feeding.
  • 3\.Patients who have known allergy to iron preparations or other medication allergies.
  • 4\.Patients who have haemochromatosis or known clinically significant liver function abnormalities.
  • 5\.The initial diagnostic MRI demonstrates intracranial haemorrhage, calcification or other susceptibility blooming artifacts.

Outcomes

Primary Outcomes

Not specified

Similar Trials